BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mezigdomide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Mezigdomide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03989414-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Regimen and to Evaluate the Safety and 
 Preliminary Efficacy of CC-92480 in Combination With Standard Treatments i
 n Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and New
 ly Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3989414
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981209-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mezigdomide: Phase 1 readout est. (NCT05981209)
DESCRIPTION:Mezigdomide\, phase 1\, Multiple Myeloma.\nStudy: Elotuzumab\, 
 CC-92480\, and Dexamethasone for the Treatment of Relapsed or Refractory M
 yeloma After CD38- and BCMA-Targeted Therapies\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /mezigdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05981209
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Mezigdomide: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Mezigdomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate Mezigdomide\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalido
 mide\, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or
  Refractory Multiple Myeloma (RRMM)\nEstimated primary completion: 10 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 19085
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06048250-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Mezigdomide: Phase 1 readout est. (NCT06048250)
DESCRIPTION:Mezigdomide\, phase 1\, Multiple Myeloma.\nStudy: Mezigdomide (
 CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed M
 ultiple Myeloma\nEstimated primary completion: 9 February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/mezigdomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06048250
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor a
 nd Backbone Treatments of Multiple Myeloma Patients\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 mezigdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT02343042
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627751-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Mezigdomide: Phase 2 readout est. (NCT06627751)
DESCRIPTION:Mezigdomide\, phase 2\, Multiple Myeloma.\nStudy: Mezigdomide\,
  Carfilzomib\, and Dexamethasone for the Treatment of Relapsed or Refracto
 ry Multiple Myeloma in Patients With Extramedullary Disease\nEstimated pri
 mary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mezigdomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06627751
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988488-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT06988488)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Schedule\, and Evaluate the Safety and 
 Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Par
 ticipants With Relapsed and/or Refractory Multiple Myeloma\nEstimated prim
 ary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mezigdomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06988488
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032714-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Mezigdomide: Phase 1 readout est. (NCT07032714)
DESCRIPTION:Mezigdomide\, phase 1\, Multiple Myeloma.\nStudy: Mezigdomide a
 nd Talquetamab in Relapsed and Refractory Multiple Myeloma\nEstimated prim
 ary completion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mezigdomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07032714
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355335-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Mezigdomide: Phase 1 readout est. (NCT07355335)
DESCRIPTION:Mezigdomide\, phase 1.\nStudy: Ziftomenib + Mezigdomide in Adol
 esc. and Adults w/ R/R AML\nEstimated primary completion: 1 July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/mezigdomide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07355335
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05651932-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mezigdomide: Phase 1 readout est. (NCT05651932)
DESCRIPTION:Mezigdomide\, phase 1\, Multiple Myeloma.\nStudy: A Study of an
  MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/mezigdomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05651932
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612787-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT07612787)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Multicent
 er Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed
  Multiple Myeloma\nEstimated primary completion: 1 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/mezigdomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07612787
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121843-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Mezigdomide: Phase 1 readout est. (NCT06121843)
DESCRIPTION:Mezigdomide\, phase 1\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate the Safety\, Effectiveness and Tolerable Dose of Arlocabtagene Auto
 leucel (BMS-986393) in Novel Combinations in Participants With Relapsed an
 d/or Refractory Multiple Myeloma\nEstimated primary completion: 1 August 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06121843
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105059-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280808
DTEND;VALUE=DATE:20280809
SUMMARY:Mezigdomide: Phase 1 readout est. (NCT07105059)
DESCRIPTION:Mezigdomide\, phase 1\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab and Mezigdomide in People With Multiple Myeloma\nEstimated prima
 ry completion: 8 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/mezigdomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07105059
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356154-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290116
DTEND;VALUE=DATE:20290117
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT07356154)
DESCRIPTION:Mezigdomide\, phase 1/2.\nStudy: A Study of Revumenib and Mezig
 domide in People With Leukemia\nEstimated primary completion: 16 January 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07356154
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348393-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Mezigdomide: Phase 2 readout est. (NCT07348393)
DESCRIPTION:Mezigdomide\, phase 2\, Multiple Myeloma.\nStudy: A Phase 2\, S
 ingle Arm Multicenter\, Study Testing Mezigdomide\, Carfilzomib\, and Dexa
 methasone (480Kd) in Participants With Relapsed or Refractory Multiple Mye
 loma (RRMM)\nEstimated primary completion: February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/mezigdomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07348393
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901868-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Mezigdomide: Phase 2 readout est. (NCT07901868)
DESCRIPTION:Mezigdomide\, phase 2\, Multiple Myeloma.\nStudy: Elranatamab W
 ith Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Mul
 tiple Myeloma\nEstimated primary completion: December 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/mezigdomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07901868
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3025@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Change in Disease Activity and Adverse Events (AE)s in Adult Partic
 ipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Ant
 ibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nE
 stimated primary completion: December 2035. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/mezigdomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
